Moderna Inc. (MRNA)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know
Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
Moderna (MRNA) Declines More Than Market: Some Information for Investors
Moderna (MRNA) reached $23.51 at the closing of the latest trading day, reflecting a -7.4% change compared to its last close.
Is it Time to Dump Your Shares of Moderna?
Although you may not exactly understand what Moderna (MRNA 3.54%) does, you probably know the company's name, given its involvement in the coronavirus pandemic. The messenger RNA technology, or mRNA, the company uses to produce medicines is exciting, and it helped fast-track a working vaccine to fight back against COVID-19.
Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop funding mRNA drug development.
Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA ) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director Stephen Hoge - President Conference Call Participants Courtney Breen - Sanford C.
Moderna slashes full-year sales outlook, reduces headcount
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares fell almost 9% in early trade as the pharmaceutical giant lowered its full-year guidance and announced a workforce reduction, overshadowing a Q2 earnings beat. The company lowered its 2025 revenue outlook by $300 million to a range of $1.5 billion to $2.2 billion, attributed to shipment timing.
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
